Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.

@article{Li2013ApoptosisrelatedMD,
  title={Apoptosis-related molecular differences for response to tyrosin kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.},
  author={Jixia Li and Bo Sheng Lv and Xiangyong Li and Zhiwei He and Keyuan Zhou},
  journal={Journal of cancer research and therapeutics},
  year={2013},
  volume={9 4},
  pages={
          668-71
        }
}
CONTEXT The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, and tyrosine kinaseinhibitors (TKIs) have been suggested as treatment. Gefitinib is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor). Both compounds compete with the binding of adenosine triphosphate (ATP) to the tyrosine kinase domain of the respective receptors to inhibit receptor autophosphorylation causing… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Similar Papers

Loading similar papers…